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Introduction: N-myc downstream-regulated gene 2 (NDRG2), a novel tumour suppressor and cell stress-related
gene, is involved in many cell metabolic processes, such as hormone, ion and fluid metabolism. We investigated
whether NDRG2 is involved in any glucose-dependent energy metabolism, as well as the nature of its correlation
with breast carcinoma.
Methods: The correlations between NDRG2 expression and glucose transporter 1 (GLUT1) expression in clinical
breast carcinoma tissues were analysed. The effects of NDRG2 on glucose uptake were assessed in breast cancer
cells and xenograft tumours. The consequences of NDRG2-induced regulation of GLUT1 at the transcription and
translation levels and the interaction between NDRG2 and GLUT1 were examined.
Results: Data derived from clinical breast carcinoma specimens revealed that (1) patients with high NDRG2
expression had better disease-free survival and overall survival than those with low NDRG2 expression and (2)
NDRG2 expression was negatively correlated with GLUT1 expression in these breast carcinoma tissues. NDRG2
inhibited glucose uptake by promoting GLUT1 protein degradation without affecting GLUT1 transcription in both
breast cancer cells and xenograft tumours. In addition, NDRG2 protein interacted and partly colocalised with GLUT1
protein in cell cytoplasm areas.
Conclusions: The results of our study support the notion that NDRG2 plays an important role in tumour glucose
metabolism, in which GLUT1 is a likely candidate contributor to glucose uptake suppression and tumour growth.
Targeting the actions of NDRG2 in cell glucose-dependent energy delivery may provide an attractive strategy for
therapeutic intervention in human breast carcinoma.Introduction
N-myc downstream-regulated gene 2 (NDRG2) is a
member of the NDRG family [1] and was first identified
and cloned in our laboratory from a normal human
brain cDNA library by subtractive hybridisation [2]. Ac-
cumulating evidence indicates that NDRG2 is a tumour
suppressor gene that is downregulated or undetectable
in many human cancers [1,3]. The overexpression of* Correspondence: nanlin-74@163.com; liyann@fmmu.edu.cn
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reproduction in any medium, provided the orNDRG2 is able to enhance cell apoptosis, inhibit cell
proliferation and suppress angiogenesis in many malig-
nant tumours [4,5]. Recently, researchers showed that
NDRG2 expression was inversely associated with TNM
(tumour, node, metastasis) stage in 189 breast carcinoma
tissues and paired normal breast tissues [6].
In addition to its known antitumoural function, NDRG2
may be a metabolism-related gene regulated by many
hormones, including adrenal steroids [7], dexametha-
sone [8,9], insulin [10-12], androgen [13], oestrogen [14]
and aldosterone [15]. NDRG2 was found to act as a regu-
lator of myoblast proliferation and can be regulated by
anabolic and catabolic factors [8]. In skeletal muscle,
NDRG2 is a substrate for several serine-threonine protein
kinases, including protein kinase B (Akt) and serum- and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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was also found to induce amiloride-sensitive Na+ trans-
port in Xenopus laevis oocytes and Fischer rat thyroid cells
[17]. In a previous study, we found that NDRG2 promoted
Na+/K+-ATPase activity to promote cell Na+ transport
and fluid balance [14]. We also identified that NDRG2
acted as a key molecule in pancreatic β cells and was in-
volved in Akt-mediated protection of β cells against lipo-
toxicity [11]. The evidence described herein suggests that
NDRG2 is a metabolism-related gene and plays important
roles in cellular physiological metabolism. Furthermore,
NDRG2 was recently shown to respond to cellular stress
under a series of environmental stress conditions [1].
However, very little information is available regarding the
function of NDRG2 in tumour metabolism.
Mammalian cells depend on glucose as a major sub-
strate for energy production [18]. Warburg showed that
tumour cells could metabolise many orders of magni-
tude larger amounts of glucose than their differentiated
normal counterparts [19,20]. The transport of glucose
across the plasma membrane is the first rate-limiting
step for glucose metabolism and is mediated via glucose
transporter proteins (GLUTs) [18]. At present, 14 mem-
bers of the GLUT family have been identified [21].
GLUT1 is broadly expressed in the body tissues and is
involved in glucose uptake in the basic state. Elevated
levels of GLUT1 have been shown to be present in many
human cancers, including head and neck, breast, lung
and ovarian [22,23]. Moreover, several reports have
suggested that GLUT1 represents potential regulatory
targets of oncogenes or tumour suppressors [24-26].
We posited the following questions: (1) whether
NDRG2 expression is associated with any GLUT expres-
sion, as well as the nature of its correlation with breast
carcinoma; (2) whether and why NDRG2 affects the
glucose uptake; (3) what would be the significance of the
interactions between NDRG2 and the GLUTs; and (4)
whether this regulation of NDRG2 on the GLUTs exists
in vivo. In our present study, we tested the hypothesis
that a possible mechanism of NDRG2 induces its partici-
pation in cancer cell energy metabolism through the
regulation of GLUTs in breast carcinoma.
Methods
Tissue samples and study cohort
This study was approved by the Ethics Committee of the
Fourth Military Medical University. All patients from
whom we obtained the 30 pairs of breast carcinoma and
adjacent normal breast tissue specimens, as well as the
269 breast carcinoma sample study cohort, provided
their full consent to participate in the study at the
Xijing Hospital of the Fourth Military Medical University
(Xi’an, China). NDRG2 and GLUT1 expression were de-
tected in all specimens. Tissue specimens were examinedseparately by two pathologists under double-blinded con-
ditions without prior knowledge of the clinical status of
the specimens.
Immunohistochemistry detection
Immunohistochemistry (IHC) was performed using the
avidin-biotin-peroxidase complex method on all breast
carcinoma samples. All sections were deparaffinised in
xylenes and dehydrated through a gradient concentration
of alcohol before endogenous peroxidase activity was
blocked using 0.5% H2O2 in methanol for 10 minutes.
After nonspecific binding was blocked, the slides were
incubated with NDRG2 antibody (1:200; Abnova, Taipei,
Taiwan) or GLUT1 antibody (1:200; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) in phosphate-buffered
saline (PBS) at 4°C overnight in a humidified container.
Biotinylated goat anti-rabbit immunoglobulin G (IgG)
(1:400; Sigma-Aldrich, St Louis, MO, USA) was incubated
with the sections for 1 hour at room temperature and
detected using a streptavidin-peroxidase complex. The
brown colour indicative of peroxidase activity was devel-
oped by incubation with 0.1% 3,3′-diaminobenzidine
(Sigma-Aldrich) in PBS with 0.05% H2O2 for 5 minutes at
room temperature. The appropriate positive and negative
controls were included in each run of IHC.
Staining evaluation
An immunoreactivity score system based on the propor-
tion and intensity of positively stained cancer cells was
applied. The two extensional standards taken were as
follows: (1) the number of positively stained cells ≤5%,
scored 0; 6% to 25%, scored 1; 26% to 50%, scored 2; 51%
to 75%, scored 3; and >75%, scored 4; and (2) the intensity
of stain colourless, scored 0; pallideflavens, scored 1; yel-
low, scored 2; and brown, scored 3. Extensional standards
(1) and (2) were multiplied, and the staining grade was
stratified as absent (score 0), weak (score 1 to 4), moderate
(score 5 to 8) or strong (score 9 to 12). Specimens were
rescored if the difference of scores from the two patholo-
gists was greater than 3. Tumours with moderate or
strong immunostaining were classified as having high ex-
pression, and tumours with absent or weak immunostain-
ing were classified as having low expression.
Cell cultures and reagents
T-47D and SK-BR-3 cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cultured
in a humidified incubator under 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen/Life
Technologies, Carlsbad, CA, USA) supplemented with
10% foetal bovine serum (FBS) and 2 mM L-glutamine.
NDRG2 antibody was purchased from Abnova. GLUT1,
hemagglutinin (HA), actin, flag and tubulin antibodies
were obtained from Santa Cruz Biotechnology.
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The cells (1 × 106 cells/well) were seeded into six-well
plates and transfected with the following constructs using
Lipofectamine 2000 (Invitrogen/Life Sciences) according
to the manufacturer’s instructions as follows: NDRG2 ex-
pression plasmid (pCMV-flag-NDRG2), GLUT1 expres-
sion plasmid (pCMV-eGFP-GLUT1), HA-ubiquitin or
small interfering RNA (siRNA) that targeted NDRG2. The
target sequences of NDRG2 siRNA and control siRNA are
given in Additional file 1: Table S1.
Gene infection
Cells were seeded into six-well plates at a density of 1 ×
106 cells/well and incubated to reach approximately 80%
confluence. After the medium was removed, adenovirus
expressing NDRG2 (Ad-NDRG2) or the negative control
adenovirus expressing LacZ (Ad-LacZ) was added to
serum-free DMEM, incubated for 2 hours, replaced with
fresh DMEM supplemented with 10% FBS and incubated
for another 48 hours. Recombinant adenoviruses carry-
ing NDRG2 or LacZ were purchased from Benyuan
Zhengyang Gene Technology Company (Beijing, China).
Immunoblotting
Both cells and breast tissues were lysed in radioimmuno-
precipitation assay buffer (0.05 M Tris-HCl (pH 7.4),
0.15 M NaCl, 0.25% deoxycholic acid, 1% Nonidet P-40,
1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin and
10 mg/ml leupeptin). Protein concentrations were mea-
sured using a bicinchoninic acid protein assay (Pierce
Biotechnology, Rockford, IL, USA). Proteins were re-
solved by SDS-PAGE and transferred to Hybond en-
hanced chemiluminescence nitrocellulose membranes
(Amersham Biosciences, Piscataway, NJ, USA). The blots
were probed with the different primary antibodies and
species-matched secondary antibodies. The bands were
detected using enhanced chemiluminescence (Pierce
Biotechnology) or the Odyssey Imaging System (LI-COR
Biosciences, Lincoln, NE, USA).
Real-time PCR
The RNA extracted from cells with TRIzol reagent
(Invitrogen/Life Technologies, Carlsbad, CA, USA) was
converted to combinational cDNA with the RevertAid
First Strand cDNA Synthesis Kit (Fermentas/Thermo
Scientific; Pittsburgh, PA, USA). Real-time PCR analysis
was performed using the Prism 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) and
the SYBR Premix Ex Taq II (Tli RNase H Plus) kit
(TaKaRa Bio, Shiga, Japan) according to the manufac-
turer’s instructions. The relative gene expression levels
were calculated using the 2−ΔΔCt method, in which
Ct represented the threshold cycle and β-actin was usedas a reference gene. The primer sequence is given in
Additional file 1: Table S1.
Cell proliferation assay
Cell growth following transfection was evaluated by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay. Cells were seeded into a 96-well plate
(1 × 104 cells per well) and incubated for 24 hours. The
cells were then incubated with 0.5 mg/ml MTT (Sigma-
Aldrich). Four hours later, the medium was replaced with
100 μl of dimethyl sulfoxide (Sigma-Aldrich) and vortexed
for 10 minutes. Absorbance was then recorded at 490 nm
using an Easy Reader 340 AT plate reader (SLT-Lab Instru-
ments, Salzburg, Austria). Relative values of optical density
were calculated as a percentage of the control. All experi-
ments were performed three times independently.
Glucose uptake assay
Prior to being harvested, adherent cultures of control and
NDRG2 adenovirus- or siRNA-treated cells in DMEM
containing 25 mM glucose were washed twice with cold
PBS and then lysed with ion-free H2O for 5 minutes on
ice. The glucose content was measured with a D-glucose
measurement kit (GAHK-20; Sigma-Aldrich) according to
the manufacturer’s protocol.
Immunofluorescence assay
Cells were fixed in a freshly prepared solution of 4%
paraformaldehyde, rinsed and permeabilised with 0.1%
Triton X-100 in PBS. Permeabilised cells were then
incubated with horse serum in PBS to block nonspecific
binding. After being washed with PBS, the cells were
incubated overnight at 4°C with mouse anti-NDRG2
antibody (diluted 1:150), rabbit anti-GLUT1 antibody
(diluted 1:150) and fluorescein isothiocyanate (FITC)-
conjugated anti-mouse antibody (diluted 1:400; Sigma-
Aldrich) or cyanine 3 (Cy3)-conjugated anti-rabbit antibody
(diluted 1:400; Sigma-Aldrich). The isotype mouse and
rabbit IgGs were used as negative controls. Dual-colour
detection was performed using a laser confocal micro-
scope after treatment with 4′,6-diamidino-2-phenylindole
(DAPI) to label nuclear DNA.
Immunoprecipitation
Transfected or untransfected cells were incubated with 1
ml of lysis buffer containing 150 mM NaCl, 50 mM
Tris-HCl (pH 7.4), 1% Lubrol (polyethylene glycolmono-
cetyl ether; MP Biomedicals, Solon, OH, USA) and 5
mM EDTA, as well as protease inhibitors, for 30 mi-
nutes at 4°C. The insoluble fraction was eliminated
through centrifugation at 10,000 × g for 30 min at 4°C.
After centrifugation, the lysates were incubated with the
antibody of interest, and protein A or G was conjugated
to sepharose (Pierce Biotechnology) for 8 hours at 4°C.
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of the lysates was saved. Beads were washed four
times with lysis buffer. Proteins were eluted in SDS-
PAGE sample buffer and separated by SDS-PAGE for
immunoblot analysis. The blots were then probed with
peroxidase-conjugated goat anti-mouse or goat anti-
rabbit antibodies and visualised by using an enhanced
chemiluminescence reagent (Pierce Biotechnology).
Xenograft study in nude mice
For inoculation into nude mice, SK-BR-3 or MDA-MB-
231 cells were washed with PBS, digested with trypsin
and resuspended in serum-free DMEM. After centrifu-
gation (800 rpm), the cell pellets were resuspended in
DMEM. The cell suspension (1 × 106 cells in a 100-ml
volume of PBS) was injected subcutaneously into the
hind legs of 4-week-old female BALB/c athymic (nu/nu)
mice (SLAC Laboratory Animal Company, Shanghai,
China). When the tumours reached a volume of approxi-
mately 200 mm3, the mice were arbitrarily assigned to
different groups (n = 6 each) to receive intratumoural
injections of 0.5, 1 or 2 × 109 plaque-forming units
(PFU) of Ad-NDRG2, 2 × 109 Ad-LacZ or PBS. Intratu-
moural injections were repeated every 3 days for a total
of 21 days. Tumours were measured (perpendicular
diameters) every 3 days, and their volumes were calcu-
lated. On day 21, the mice were killed and their tumours
were removed for analysis. Tumour volumes were calcu-
lated based on caliper measurements of the length and
width of the lesions using the following formula: 0.5 ×
length × (width2). The tumour growth curve was then
derived from these data.
All of the experimental procedures were conducted in
accordance with the Detailed Rules for the Administra-
tion of Animal Experiments for Medical Research Pur-
poses issued by the Ministry of Health of China and
received ethical approval by the Animal Experiment Ad-
ministration Committee of the Fourth Military Medical
University (Xi’an, China). All efforts were made to min-
imise the animals’ suffering and reduce the number of
animals used.
Statistical analysis
In vitro experiments were performed three times, and
each experiment was performed in triplicate. Data from
all quantitative assays are expressed as the means ± SD
and were analysed statistically using one-way analysis of
variance, independent samples t-test or Student’s t-test.
In the clinical specimens study, the associations between
NDRG2 expression and categorical variables were ana-
lysed using the χ2 test or Fisher’s exact test as appropri-
ate. Correlations between NDRG2 expression and the
expression of other molecules were analysed by using
the Spearman correlation test. Kaplan–Meier analysiswas used to evaluate disease-free survival and overall
survival. P < 0.05 was considered statistically significant.
Results
Relationship between NDRG2 expression and clinical
histopathological characteristics in breast carcinoma
To assess the significance of NDRG2 protein expression
in the development and progression of breast cancer, we
compared the histopathological characteristics of 269
breast cancer samples with available NDRG2 protein sta-
tus. The correlations between NDRG2 expression and
different clinical histopathological factors are presented
in Table 1. Significant correlations were found between
low NDRG2 expression and advanced TNM staging
(P < 0.0001), high proliferation index (Ki67 status;
P = 0.006), positive human epidermal growth factor re-
ceptor 2 (HER2) status (P = 0.010) and poor histological
differentiation (P < 0.0001). However, high NDRG2 ex-
pression was correlated with positive oestrogen receptor
(ER) status (P = 0.010). Correlation coefficients are pre-
sented in Table 2. Furthermore, Kaplan–Meier analysis
was used to evaluate the disease-free survival and overall
survival of patients with breast cancer and NDRG2 pro-
tein expression. The results show that patients with high
NDRG2 expression in breast tumour tissues had better
disease-free survival than those with low NDRG2 ex-
pression (P = 0.0066 by logrank test) (Figure 1A). Breast
cancer patients with low NDRG2 expression had a
higher risk of relapse than those with high NDRG2
expression. A statistically significant association between
long overall survival and high NDRG2 protein levels was
found in breast cancer patients. Breast cancer patients
with high NDRG2 expression had longer overall survival
than patients with low NDRG2 expression P = 0.0007 by
logrank test) (Figure 1B).
Correlation of NDRG2 expression with GLUT1 expression
in breast carcinoma
Tumour cells depend on glucose as a major substrate for
energy production, and many tumour suppressor genes
play important roles in the regulation of glucose metabol-
ism [27]. GLUT1 is broadly expressed in the body tissues
and is also involved in glucose uptake in the basic state,
especially so for tumour glucose metabolism [18]. In our
present study, we first investigated this relationship
between NDRG2 and GLUT1 expression by IHC and
immunoblotting in 30 pairs of breast carcinoma and
adjacent normal breast tissue specimens. Positive staining
of anti-NDRG2 was found predominantly in the cyto-
plasm of both normal breast cells and breast cancer cells,
but weaker staining for NDRG2 was observed in the can-
cer specimens compared with normal tissues. Conversely,
strong positive staining of GLUT1 was observed in the
cytoplasm and cytosolic membrane of tumour cells, and
Table 1 Statistical results of NDRG2 expression in 269 breast cancer specimens
Variables N
NDRG2 expression
P-valueLow expression, n (%) High expression, n (%)
Age (years) 0.104b
≤50 112 72 (64.3) 40 (35.7)
>50 157 85 (54.1) 72 (45.9)
Tumour size 0.536b
≤2 cm 121 68 (56.2) 53 (43.8)
>2 cm 148 89 (60.1) 59 (39.9)
TNM stage <0.0001b
I to II 114 48 (42.1) 66 (57.9)
III to IV 155 109 (70.3) 46 (29.7)
Lymph node metastasis 0.009b
Negative 114 56 (49.1) 58 (50.9)
Positive 155 101 (65.2) 54 (34.8)
Histology <0.0001c
Poorly differentiated 103 75 (72.8) 28 (27.2)
Moderately differentiated 83 52 (62.7) 31 (37.3)
Well differentiated 83 30 (36.1) 53 (63.9)
Tumour invasion 0.387b
No 134 82 (61.2) 52 (38.8)
Yes 135 75 (55.6) 60 (44.4)
ER status 0.010b
Negative 79 56 (70.9) 23 (29.1)
Positive 190 101 (53.2) 89 (46.8)
Her-2 status 0.010b
Negative 201 108 (53.7) 93 (46.3)
Positive 68 49 (72.1) 19 (27.9)
Ki67 status 0.006b
Negative 119 58 (48.7) 61 (51.3)
Positive 150 99 (66.0) 51 (34.0)
aER, Oestrogen receptor; Her-2, Human epidermal growth factor receptor 2; NDRG2, N-myc downstream-regulated gene 2; TNM, tumour, node, metastasis. bFisher’s
exact test was used for statistical analyses. P < 0.05 were considered statistically significant. cPearson’s χ2 test was used for statistical analyses.
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(Figure 1C and Additional file 2: Figures S1 and S2).
Furthermore, immunoblotting data revealed that NDRG2
protein expression in cancer samples was much lower
than that in the paired adjacent normal tissue. However,
GLUT1 expression was higher in cancer tissue than in the
paired adjacent normal tissue (Figure 1D and Additional
file 2: Figure S3). Indeed, in normal tissue and cancer
tissue, the means of immunoreactivity score of NDRG2
IHC staining were 6.03 and 1.97 (Figure 1E), respectively,
and the means of immunoreactivity score of GLUT1, IHC
Staining were 3.13 and 6.53 (Figure 1F), respectively. Simi-
larly, we identified the degree of correlation between
NDRG2 expression and GLUT1 expression in 269 breast
cancer specimens. The Spearman correlation analysisindicated that NDRG2 protein expression was inversely
correlated with GLUT1 expression (Pearson correlation
coefficient rs = −0.179; P = 0.003) (Table 3). The data
imply that NDRG2 expression might be involved in the
development and progression of breast cancer and that
NDRG2 expression is inversely correlated with GLUT1
expression in breast carcinoma.
NDRG2 inhibits the growth of breast cancer cells in both
high- and low-glucose medium
Next, we sought to explore the regulatory mechanism of
NDRG2 in tumour glucose metabolism. To investigate
the effect of NDRG2 on breast cancer cell proliferation
in high-glucose (25 mM) or low-glucose (5.5 mM)
medium, we designed the following assays. First, the
Table 2 Correlation of NDRG2 expression with clinical




Correlation coefficient (rs) P-value
Age (years) 0.101 0.097
Tumour size −0.040 0.516
TNM stage −0.283 0.0001
Lymph node metastasis −0.161 0.008
Differentiation status 0.301 0.0001
Tumour invasion 0.057 0.350
ER status 0.164 0.007
Her-2 status −0.162 0.008
Ki67 status −0.174 0.004
aER, Oestrogen receptor; Her-2, Human epidermal growth factor receptor 2;
NDRG2, N-myc downstream-regulated gene 2; TNM, Tumour, node, metastasis.
Spearman’s correlation test was used for statistical analyses. P < 0.05 was con-
sidered statistically significant.
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was examined by immunoblotting. The results showed
that the expression of NDRG2 was relatively high in
T-47D cells and relatively low in SK-BR-3 cells (Figure 2A).
In the following studies, we chose T-47D and SK-BR-3
cells as experimental models. Next, the adenovirus carry-
ing NDRG2 (Ad-NDRG2) or the siRNA targeting NDRG2
(NDRG2 siRNA) was applied to upregulate or knock
down, respectively, the level of NDRG2. After infection by
Ad-NDRG2 in SK-BR-3 or transfection by NDRG2 siRNA
in T-47D cells, the expression of NDRG2 was successfully
increased or decreased (Figure 2B). Moreover, these ef-
fects were more prominent with increasing concentrations
of Ad-NDRG2 or NDRG2 siRNA (Figures 3A to 3D). The
results of the MTT assays showed that in both high- and
low-glucose medium, the overexpression of NDRG2 inhib-
ited SK-BR-3 cells proliferation (Figure 2C) and silencing
NDRG2 promoted T-47D cell proliferation (Figure 2D). In
high-glucose medium, however, the effects of NDRG2 on
cell proliferation were more prominent.
NDRG2 could decrease the intracellular glucose level of
breast cancer cells
Given that the antiproliferative effects of NDRG2 on
breast cancer cells were more prominent in high-glucose
medium, we investigated whether NDRG2 would affect
the capacity of these cells to take in glucose. First, the
effect of the glucose culture environment on NDRG2
expression was investigated. Immunoblot analysis re-
vealed that, after exposure to different concentrations
of glucose medium, the transcription and translation
levels of NDRG2 increased with increasing glucose levels
(Figures 2E and 2F). In addition, we checked the intra-
cellular glucose content to assess the extent to whichNDRG2 contributed to cell glucose uptake. Glucose up-
take was decreased with increasing Ad-NDRG2 treatment
in SK-BR-3 cells (Figure 2G). T-47D cells were transfected
with NDRG2 siRNA at different concentrations, and glu-
cose uptake was significantly augmented with increasing
NDRG2 siRNA administration (Figure 2H). These data
suggest that a high-glucose microenvironment could pro-
mote NDRG2 expression and that NDRG2 could inhibit
glucose intake in breast cancer cells.
NDRG2 negatively regulates GLUT1 levels in breast cancer
cells
The transport of glucose across the plasma membrane is
the first rate-limiting step for glucose metabolism and is
mediated via GLUTs. GLUTs play critical roles in glu-
cose uptake, especially in tumour cells. To investigate
whether GLUTs are regulated by NDRG2, GLUT1/2/3/4
protein levels were measured in SK-BR-3 cells infected
with Ad-NDRG2 or T-47D cells transfected with NDRG2
siRNA in a high-glucose medium. Immunoblot analysis
revealed that GLUT1 protein levels were decreased by in-
creases in Ad-NDRG2-mediated NDRG2 overexpression,
but that GLUT1 protein levels were increased with
NDRG2 siRNA treatment (Figures 3A and 3B). There
were no changes in the intensity of anti-GLUT2 and anti-
GLUT4 bands from treated cells compared with the un-
treated controls. GLUT3 was nearly undetectable in both
the SK-BR-3 and T-47D cells (Figures 3A and 3B). How-
ever, the data obtained from real-time PCR showed that
GLUT1 transcriptional levels were not significantly chan-
ged with NDRG2 up- or downregulation (Figures 3E and
3F). Because the amount of GLUT1 protein can be modi-
fied by changes in the rate of synthesis or degradation,
we hypothesised that NDRG2 may exert an effect on the
degradation of GLUT1. To test this hypothesis, we added
the ubiquitin-proteasome inhibitor MG-132 with the
Ad-NDRG2-treated SK-BR-3 cells. As shown in Figure 3G,
the addition of MG-132 rescued GLUT1 protein levels,
indicating that the decrease in GLUT1 in response
to NDRG2 overexpression was due to proteasome-
dependent degradation. GLUT1 protein is synthesised and
degraded in the cytosol, whereas GLUT1 protein enacts its
biological function primarily when it is transported to the
cell membrane. So, we separated the membrane and cyto-
solic content of cells to detect GLUT1 protein distribution
changes. As shown in Figure 3H, the amount of GLUT1 in
the membrane and cytosolic fractions was substantially
decreased in NDRG2-overexpressed SK-BR-3 cells. In
addition, the immunoprecipitation data revealed that
ectopic NDRG2 expression led to an increase in GLUT1
ubiquitination (Figure 3I and Additional file 2: Figure S4).
These results suggest that NDRG2 is able to promote
GLUT1 ubiquitination and degradation and can lead to
decreased GLUT1 protein level.
Figure 1 NDRG2 is correlated with increased survival and negatively correlated with GLUT1 in breast carcinoma. Kaplan–Meier analysis
was carried out according to N-myc downstream-regulated gene 2 (NDRG2) expression levels of disease-free survival (A) and overall survival
(B). (C) Serial immunostained sections for NDRG2 and glucose transporter 1 (GLUT1) in breast cancer and normal tissues were analysed. Original
magnification, 40× (top) and 400× (bottom); scale bars = 50 μm. (D) Protein was extracted from matched breast tumour tissue (T) and adjacent
normal tissue (N) and subjected to immunoblot analysis to examine NDRG2 and GLUT1 expression. β-actin served as a loading control. P: patient.
Relative expression levels of NDRG2 (E) and GLUT1 (F) in human breast cancer and adjacent normal tissue are shown. immunoreactivity score dis-
tribution of cancer and adjacent normal tissue were represented with black and brown closed circles, respectively. The horizontal lines presented
are means; error bars represented SD from 30 samples. P < 0.01 was considered a statistically significant difference.
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Table 3 Correlation of NDRG2 expression with GLUT1 expression in 269 breast cancer specimensa
Variable N
NDRG2 expression
PbLow expression, n (%) High expression, n (%)
GLUT1 0.003c
Low expression 130 64 (49.2) 66 (50.8)
High expression 139 93 (66.9) 46 (33.1)
aGLUT1, Glucose transporter protein 1; NDRG2, N-myc downstream-regulated gene 2. bSpearman correlation test was used for statistical analyses. P < 0.05 was
considered statistically significant. cSpearman correlation coefficient (rs) = −0.179.
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Our observation that NDRG2 regulated GLUT1 protein
stability prompted us to examine the interaction be-
tween NDRG2 and GLUT1 and their subcellular distribution.
Confocal microscopy was applied to observe the sub-
cellular localisation of NDRG2 and GLUT1 in SK-BR-3
cells. We found that a portion of endogenous NDRG2 and
endogenous GLUT1 was colocalised in the cytoplasmic
region of SK-BR-3 cells (Figure 4A). The colocalisation
suggests that NDRG2 and GLUT1 may physically interact
with each other. To establish whether NDRG2 physically
associates with GLUT1, coimmunoprecipitation was
performed using lysates prepared from SK-BR-3 cells.
A 41-kDa protein that corresponds to NDRG2 was
precipitated by anti-GLUT1 antibody and probed by
anti-NDRG2 antibody, and a 55-kDa protein correspond-
ing to GLUT1 was precipitated by the anti-NDRG2
antibody and probed by anti-GLUT1 antibody (Figure 4B).
We also demonstrated that exogenous GLUT1 coim-
munoprecipitated with exogenous NDRG2 in HEK293
cells that were cotransfected with pCMV-flag-NDRG2
and pCMV-eGFP-GLUT1 plasmids and vice versa
(Additional file 2: Figure S5). Collectively, the results
of these experiments indicated that NDRG2 bound
to GLUT1.NDRG2 decreases glucose uptake and GLUT1 protein
level in subcutaneous xenograft tumours
We found that NDRG2 could induce GLUT1 protein
degradation to decrease glucose uptake in breast cancer
cell lines, but whether this regulatory mechanism also
functions in the tumour microenvironment must be
studied in vivo. We injected Ad-NDRG2 at the concen-
trations of 0.5, 1 and 2 × 109 PFU or 2 × 109 PFU Ad-
LacZ every 3 days into preestablished human SK-BR-3
breast tumours (approximately 200 mm3) grown in nude
mice. As shown in Figure 5A, the Ad-NDRG2 group
that received injections at 2 × 109 PFU achieved a sus-
tained and significant arrest of tumour growth (68%
decrease in mean tumour volume on day 21 compared
with Ad-LacZ group). The mice were killed at 21 days
after the first intratumoural injection, and the tumours
were removed for analysis of the glucose uptake and
protein levels of NDRG2 and GLUT1. We found thatthe glucose uptake of tumour cells was inhibited signifi-
cantly with increased Ad-NDRG2 compared with the
Ad-LacZ group (Figure 5B). Consistent with the results
of in vitro experiments (Figure 3A), increased NDRG2
was correlated with decreased GLUT1 in the xenograft
tumours (Figure 5D and Additional file 2: Figure S6). In
addition, obvious positive NDRG2 staining was detected
by IHC in tumours excised from mice in the 2 × 109
PFU Ad-NDRG2 group. However, GLUT1 staining was
weaker in the Ad-NDRG2 group compared with the
Ad-LacZ group (Figure 5C). We repeated the xenograft
tumour experiments with MDA-MB-231 cells, a highly
metastatic cell line, and the results (Additional file 2:
Figure S7) were consistent with those of SK-BR-3 cells.Discussion
Understanding the mechanisms involved in cancer cell en-
ergy metabolism may provide a reasonable interpretation
for the function of NDRG2 as a tumour suppressor. To
the best of our knowledge, we report for the first time that
NDRG2 participated in cellular glucose uptake by regulat-
ing the protein stability of GLUT1. We also found that
NDRG2 adenovirus can be used to treat breast cancer by
inhibiting cellular glucose uptake in a nude mouse xeno-
graft model. Consistent with the cell- and animal-based
results, a significantly inverse correlation between NDRG2
and GLUT1 expression was observed in clinical breast
cancer tissue specimens.
Much of the data obtained from tissue of breast cancer
patients presented herein are supportive of previously
published work by Oh et al. [6]. Although researchers in
several studies have reported that NDRG2 inhibited
breast cancer cell survival and other malignant activities
[5,28-30], the available clinical data before the publica-
tion by Oh et al. were very limited [6]. Liu et al. previ-
ously reported that there was a reduction in NDRG2
mRNA levels in 5 of 21 breast cancer tissue samples
tested compared with normal tissues [31]. Anders et al.
found that NDRG2 protein was reduced in breast cancer
tissue based on a slightly larger sample set (N = 35) [32].
Recently, the correlation between NDRG2 expression
level and clinical meaning was summarized by Oh et al.
in 189 breast cancer patients who had undergone surgi-
cal resection [6]. Similarly to Oh et al.’s data set derived
Figure 2 NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. (A) T-47D, MCF-7, Bcap37,
MDA-MB-231 and SK-BR-3 cells were collected for the extraction of proteins and analysed for N-myc downstream-regulated gene 2 (NDRG2)
expression by immunoblotting. (B) SK-BR-3 cells with low NDRG2 expression were infected by an adenovirus carrying NDRG2 (Ad-NDRG2) or
negative control LacZ (Ad-LacZ), and T-47D cells with high NDRG2 were transfected with small interfering RNA targeting NDRG2 (NDRG2 siRNA)
or negative control siRNA (Con siRNA). Thereafter proteins were extracted from these cells and analysed by immunoblotting. β-actin was used
as a loading control. Before being cultured in 25 mM high-glucose (H.G.) or 5.5 mM low-glucose (L.G.) medium, SK-BR-3 cells were infected
by Ad-NDRG2 (C) and T-47D cells were transfected by NDRG2 siRNA (D). Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay for 1 to 5 days. (C) and (D) The data presented are means ± SD for three independent experiments; error bars
represent SD from 8 replicative wells. (C) *P < 0.05 and **P < 0.01 versus H.G. Ad-LacZ. #P < 0.05 versus L.G. Ad-LacZ. (D) *P < 0.05 versus H.G.
Con siRNA. (E) and (F) SK-BR-3 cells were cultured to glucose medium at concentrations of 0, 5, 25, 50 and 100 mM for 24 hours, and then the
protein or mRNA was extracted for analysis by immunoblotting (E) or real-time PCR (F). β-actin was used as a loading control. The data presented
are means ± SD; error bars represented SD from 3 replicative wells. *P < 0.05 and **P < 0.01 versus control group. (G) SK-BR-3 or (H) T-47D cells,
respectively, were infected with Ad-NDRG2 or transfected NDRG2 siRNA and cultured in a high-glucose medium (25 mM) for 48 hours. Next, cell
glucose concentrations were measured. (G) and (H) The data presented are means ± SD of three independent experiments; error bars represent
SD from 8 replicative wells. *P < 0.05 and **P < 0.01 versus control group.
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http://breast-cancer-research.com/content/16/2/R27from 189 breast carcinoma patients, we show in our
present study that, in specimens obtained from 269
breast cancer patients, low NDRG2 expression wasassociated with advanced TNM stage, high Ki67 and
HER2 expression and poor histological differentiation.
We also found that breast cancer patients with high
Figure 3 NDRG2 downregulates GLUT1 by promoting its ubiquitination. (A), (C) and (E) SK-BR-3 cells were infected with an adenovirus
carrying N-myc downstream-regulated gene 2 (Ad-NDRG2) at 1, 5 and 10 multiplicity of infection (MOI) or Ad-LacZ for 48 hours. (B), (D) and (F) T-47D
cells were transfected with NDRG2 small interfering RNA (siRNA) 10, 25 and 100 pmol or control siRNA for 48 hours. Next, cell proteins or mRNA were
extracted and analysed by immunoblotting (A) and (B) or by real-time PCR (C) to (F). β-actin was used as a loading control. (C) – (F) The data pre-
sented are the means ± SD of three independent experiments; error bars represent SD from 3 replicative wells. *P < 0.05 and **P < 0.01 versus control
group. (G) SK-BR-3 cells were infected with 10 MOI Ad-NDRG2 or Ad-LacZ for 48 hours and then treated with 2 μM, 6 μM or 8 μM MG-132 for 4 hours.
Next, the protein was extracted and analysed by immunoblotting. (H) Cell fractions were prepared from the SK-BR-3 cells infected with 10 MOI Ad-
NDRG2 or Ad-LacZ for 48 hours, and the membrane and cytosolic fractions of endogenous glucose transporter 1 (GLUT1) protein were detected. Tubulin
and β-actin served as loading controls. (I) SK-BR-3 cells were transfected with hemagglutinin (HA)-ubiquitin plasmid for 6 hours and infected with Ad-NDRG2 or
Ad-LacZ for another 48 hours. Subsequently, the cell lysates were collected and analysed by immunoprecipitation (IP) and immunoblotting with GLUT1
and HA antibodies. WB, Western blot.
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Figure 4 NDRG2 interacts with GLUT1. (A) SK-BR-3 cells were fixed and incubated with primary antibodies against N-myc downstream-regulated
gene 2 (NDRG2) or glucose transporter 1 (GLUT1) and with fluorescein isothiocyanate or a cyanine 3 secondary antibody. Green fluorescence indicates
NDRG2 expression, red fluorescence indicates GLUT1 expression and blue fluorescence indicates nuclear staining. The results of the merged images
reveal that NDRG2 and GLUT1 were colocalised in the cytoplasm. (B) Immunoprecipitation (IP) assays were performed with whole-cell lysates of
SK-BR-3 cells pretreated with protein A–conjugated sepharose beads. Whole-cell lysates were probed for input. The antibodies for immunoprecipitation
and Western blot (WB) analyses were carried out as indicated. The locations of various proteins are indicated by arrowheads. IgG, Immunoglobulin G.
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better overall survival compared with patients with low
NDRG2 expression. However, by Oh et al. showed that
high NDRG2 expression correlated only with favourable
recurrence-free survival, not with overall survival [6].
Further observations are needed to confirm the correl-
ation of NDRG2 and breast carcinoma prognosis.
Additionally, in our present study, NDRG2 expression
was inversely correlated with GLUT1 expression in
patient specimens, which is in agreement with our
cell- and animal-based results.
Many tumour suppressor genes play important roles
in the regulation of glucose metabolism, in addition to
their established roles in cell survival and apoptosis. p53,
one of the most highly studied tumour suppressors,
which can upregulate NDRG2 expression [4], has been re-
ported to reduce intracellular glucose levels by inhibiting
the expression of GLUTs [27]. For example, p53 directly
represses the transcriptional activity of GLUT1 andGLUT4 gene promoters [33]. In addition, p53 represses
GLUT3 gene expression indirectly by preventing the acti-
vation of the inhibitor of the nuclear factor κB pathway
[34]. In our present study, we show that NDRG2 could
regulate GLUT1 posttranslational modification without
affecting other glucose transporters, including GLUT2,
GLUT3 and GLUT4. We also found that NDRG2
decreased GLUT1 protein stability by promoting the
ubiquitin-mediated protein degradation pathway, whereas
the transcription levels of both GLUT1 and other GLUT
genes were not affected.
Investigators in previous studies have shown that the
expression of NDRG2 is regulated by some transcription
factors, including p53 [4], Myc [35] and Hif-1 [36].
NDRG2 is a novel p53-inducible target involved in the
p53-mediated apoptosis pathway in lung cancer cells [4],
and the expression of NDRG2 was upregulated by Hif-1
in tumour cells under hypoxic conditions [36]. However,
the expression of human NDRG2 is downregulated by
Figure 5 NDRG2 decreases the glucose uptake and GLUT1 protein levels in SK-BR-3-based subcutaneously xenograft tumours. The
experiments illustrated are described in the Methods section. (A) Tumour growth was assessed every 3 days until day 21 treatment by measuring
two perpendicular diameters and calculating the volume in cubic centimetres. Ad-LacZ, adenovirus expressing LacZ; Ad-NDRG2, adenovirus
expressing NDRG2; PFU, Plaque-forming units. The data presented are means ± SD; error bars represent SD from 6 mice. *P < 0.05 and **P < 0.01
versus phosphate-buffered saline (PBS) or Ad-LacZ. (B) Tumour cells were dissociated from xenograft tumours and suspended in PBS after
the number of cells was counted. Next, the glucose uptake of cells in each group was detected. The data presented are means ± SD of three
independent experiments; error bars represent SD from 6 mice. *P < 0.05 and **P < 0.01 versus PBS or Ad-LacZ. (C) Intratumoural protein
expression was assessed by N-myc downstream-regulated gene 2 (NDRG2) and glucose transporter 1 (GLUT1) IHC staining. Representative
images are shown. Original magnification: 400 x; Scale bars = 50 μm. (D) Proteins of the xenograft tumours from each group were extracted
and analysed by immunoblotting to quantify NDRG2 and GLUT1 protein changes.
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http://breast-cancer-research.com/content/16/2/R27Myc via transcriptional repression [35]. c-Myc directly
transactivates genes encoding GLUT1 protein and in-
creases glucose uptake in Rat1 fibroblasts [37]. Under
hypoxic conditions, a transcription factor complex in-
cluding Hif-1α was shown to bind the GLUT1 promoter
to upregulate GLUT1 mRNA expression [38]. Interest-
ingly, among the above-mentioned transcription factors,
p53 might promote NDRG2 expression [4] and inhibit
GLUT1 transcriptional activity [33], and Myc might sup-
press NDRG2 expression [35] and transactivate GLUT1
[37]. NDRG2 and GLUT1 were inversely regulated by p53
[4,33] and Myc [35,37], which suggests that NDRG2 may
function as a tumour suppressor by decreasing glucose
uptake. Surprisingly, Hif-1 increases the expression of both
NDRG2 [36] and GLUT1 [38]. We cannot explain why Hif-
1 positively regulates both NDRG2 and GLUT1 in a man-
ner different from p53 or Myc. We hypothesise that this
difference is due to the fact that Hif-1-related experiments
were performed under different hypoxic conditions and cell
physiological contexts. Whether hypoxia-inducible factors
are involved in NDRG2-mediated GLUT1 content and glu-
cose intake regulation in breast cancer needs to be directly
determined in future studies.NDRG2 appears to be broadly involved in stress
responses, cell proliferation and cell differentiation [1].
The proteins with which NDRG2 interacts may provide
important information contributing to understanding its
precise molecular and cellular functions. Our previous
study characterised a cell-cycle-dependent transcription
factor, MSP58, as a binding partner of NDRG2. NDRG2
may colocalise with MSP58 in the nuclear region of
the HeLa cell during cell stress [39]. In another of
our previous studies, we found that the β1 subunit of
Na+/K+-ATPase interacted and colocalised with NDRG2
in the perinuclear cytoplasmic region in human salivary
cells and that NDRG2 could protect the β1 subunit pro-
tein and inhibit its degradation [14]. In that previous
study, we detected that NDRG2 bound to and partly
colocalised with GLUT1 in the cytoplasmic region of
breast cancer cells. We showed that NDRG2 can de-
crease GLUT1 protein stability and promote the ubiqui-
tination and degradation of GLUT1. Collectively, these
experiments imply that NDRG2 might act as some kind
of chaperone molecule that is involved in regulating pro-
tein stability in different cell physiological contexts.
However, the currently available bioinformatics analysis
Ma et al. Breast Cancer Research 2014, 16:R27 Page 13 of 14
http://breast-cancer-research.com/content/16/2/R27does not indicate any known motif or domain in NDRG2
[40], and, to the best of our knowledge, there is no pub-
lished literature indicating that NDRG2 is an E3 ubiquitin
ligase. Mass spectrometric analysis could be used to
screen for the ubiquitin-related proteins that interact with
both NDRG2 and GLUT1. However, this hypothesis must
be determined directly in future studies.
Conclusions
To the best of our knowledge, the data produced in our
present study provide the first evidence that NDRG2, a
tumour suppressor, is negatively correlated with GLUT1
expression in breast carcinoma. This correlation is asso-
ciated with a better prognosis in breast carcinoma pa-
tients. We have further demonstrated that NDRG2 plays
an important role in tumour cell glucose transport, dur-
ing which NDRG2 promotes the degradation GLUT1
protein to suppress glucose uptake in breast cancer cells
in vivo and in vitro. Although the contribution of
NDRG2 to tumour homeostasis is complicated and not
yet fully understood, our findings provide a better un-
derstanding of the energy metabolism of tumours.
NDRG2 may be viewed as an attractive therapeutic
target for breast carcinoma.
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